Fabrinet vs DENTSPLY SIRONA Inc — how do they compare? Fabrinet trades at $467.23 (market cap $17.44B), while DENTSPLY SIRONA Inc trades at $13.83 (market cap $2.68B). The key difference: Fabrinet is far larger — about 6.5× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Fabrinet pays none. Which is the better fit depends on your goals.
| FN | XRAY | |
|---|---|---|
Market Cap | $17.44B | $2.68B |
Sector | Technology | Health |
52-Week High | $746.47 | $16.85 |
52-Week Low | $277.04 | $9.64 |
Enterprise Value | $16.50B | $4.83B |
Dividend Yield | — | 5.04% |
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $474.19, down 1.78% on the day, with a bearish technical signal despite strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.72 exceeding expectations. Analyst consensus remains strongly bullish with a $733 price target, though technical indicators show selling pressure with support at $473 and resistance at $484.
FN presents a compelling growth story driven by AI infrastructure demand, with revenue projected to grow from $3.42B to $4.2B in 2026. However, premium valuation metrics (P/E 41.81, P/B 7.57) and technical bearishness create near-term headwinds. The risk-reward favors long-term investors given the company's strategic positioning in optical communications and debt-free balance sheet.
Dentsply Sirona (XRAY) trades at $12.70, down 0.63% with bearish profitability metrics including negative net income margin and ROE. The stock shows mixed technical signals with bullish moving averages but overbought RSI levels. Recent earnings have consistently missed expectations, though the company maintains a 48.93% gross margin and is expanding its US distribution network with new partnerships and AI-enabled product launches.
While analyst consensus leans Hold with a $13.33 price target, the stock faces significant fundamental challenges including declining revenue, negative earnings, and rising debt-to-asset ratios. Near-term catalysts include the Q2 2026 earnings report and continued execution of the Return-to-Growth plan, but investors should weigh the high valuation multiples against persistent profitability concerns.
Trailing returns across standard periods
Latest headlines on both assets
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →